Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

Inclusion Criteria

• •1. Age ≥18, male or female.
• •2. Patients must provide written informed consent to participate in the study.
• •3. Patients must have biopsy proven unresectable stage III NSCLC (AJCC 8th).
• •4. Patients must has sensitizing EGFR mutation (e.g. exon 19 deletion or exon 21 L858R).
• •5. Patients receiving almonertinib for 3 months and achieved stable disease, partial response or completely response.
• •6. ECOG score 0-1
• •7. Demonstrate adequate organ function Patients evaluated as Cr, PR and SD were given concurrent chemoradiotherapy 3 months after targeted therapy